Skip to main content

Cronos Group Inc fell short of quarterly revenue estimates on Tuesday, as the Canadian producer’s revenue per gram of cannabis sold fell in a market suffering from surplus supply.

The cannabis industry in the country is facing a supply glut as companies ramp up production. But retail sales have failed to offset the surplus, even though there has been a rise in the number of weed stores and the sale of cannabis-derivative products has been allowed in Canada.

Cronos said its net product revenue per gram sold outside the United States nearly halved to $3.75 in the third quarter, dulling a 31-per-cent improvement in cost of sales per gram sold.

Story continues below advertisement

Total operating expenses rose nearly five fold to $34.8-million, driven by a surge in general and administrative expenses.

Higher spending on research and development, acquisitions and expanding in new markets has weighed on cannabis companies’ profitability, with the sector down about 25 per cent this year.

Cronos said cannabis sales rose six fold to 3,142 kilograms outside the United States, primarily driven by increased cannabis production.

The Toronto-based company reported a wider-than-expected adjusted core loss of $23.9-million, in the quarter ended Sept. 30, compared with the average analyst estimate of $19.87-million, according to IBES data from Refinitiv.

Revenue rose more than three fold to $12.70-million, but missed expectations of $14.14-million.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies